BSECompany Update1 Oct 2026 · 1 Oct 2026, 02:02 pm
Appointment of Statutory Auditor of the Company
Asston Pharmaceuticals Ltd · 544445
✦ AI SummaryMgmt Change
Asston Pharmaceuticals Ltd has announced the appointment of Mr. Ashish Narayan Sakalkar as Director retiring by rotation and re-appointment, and M/s Panchal S K & Associates as Statutory Auditors of the Company.
Analysis Scores
Earnings Impact2/10
Growth Catalyst3/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Asston Pharmaceuticals Ltd - 544445 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Attachments (1)
📄pdf
Download →
910435be-1a07-4893-9631-147c3d6ad38a.pdf
View document text
ASSTON PHARMACEUTICALS LIMITED
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)
To, Date: 01/10/2026
BSE Limited (BSE Ltd)
Listing / Compliance Department,
Dalal Street, Mumbai – 400001
BSE Scrip Code: 544445
Subject: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015
Dear Sir/Madam,
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015, read with Schedule III of the said Regulations, we are pleased to inform you that members of
the company have approved the following resolution:
1. Receipt, consideration and adoption of the Audited Standalone financial statements of the
Company for the financial year ended March 31, 2026 together with the reports of Board of
Directors and of the Auditors thereon.
2. Approved appointment of Mr. Ashish Narayan Sakalkar (DIN: 06601011), Managing Director of
the Company, as Director retiring by rotation and re-appointment by the members of the
Company pursuant to section 152 (6) of the Companies Act, 2013. (Annexure-A)
3. Approved appointment of M/s Panchal S K & Associates (Peer Review Certificate No. 018089
and Firm Registration No. 145989W) as Statutory Auditors of the Company (Annexure-B).
4. Approved increase in remuneration of Mr. Ashish Narayan Sakalkar (DIN: 06601011),
Managing Director of the Company
5. Approved increase in remuneration of Mrs. Saili Jayaram More (DIN: 02691527), Whole-time
Director and CEO of the Company;
6. Approved increase in remuneration of Mr. Sachin Chandrakant Badakh (DIN: 08685214), Non-
Executive Director of the Company;
You are requested to please take note of the same.
For Asston Pharmaceuticals Limited
Rishi Upadhaya
Company Secretary and Compliance Officer
A74234
Place: Mumbai
Enclosed as above
CIN: U24304MH2019PLC324187
Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi
Mumbai, Thane, Maharashtra, 400614, India
Phone No.: 022-49731419 / 49731411, Email id:
aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com
Web: www.asstonpharmaceuticals.com
ASSTON PHARMACEUTICALS LIMITED
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)
Annexure-A
SR.NO. Particulars Details
1 Reason for Change viz appointment, Mr. Ashish Narayan Sakalkar(DIN: 06601011),
Re-appointment, Resignation, Managing Director, has been re-appointed as
removal, death or otherwise Managing Director of the company through
members' approval via a shareholder
resolution passed in the 7th Annual General
Meeting held on 29th September, 2026, and
was liable to retire by rotation, being re-
appointed in terms of Section 152 (6) of the
Companies Act, 2013
2 Term of appointment/reappointment Re-appointed as per the provisions of Section
152(6) of the Companies Act, 2013.
3 Brief profile (in case of appointment) Ashish Narayan Sakalkar aged 50 years is the
(In case of Appointment) Managing Director of our Company. He has
completed his Master of Science in the year
2001 from the Department of NMU, Jalgaon
and PHD from JJT University, and also a
Diploma in Regulatory Affairs from the
University of Delhi. He has good experience in
the field of Industrial Chemistry, Quality
Assurance and Regulation. He handles the
overall business operations of the company
and mainly focuses on business expansion,
customer acquisition, and negotiation with
suppliers.
4 Disclosure of relationships between Mr. Ashish Narayan Sakalkar (DIN: 06601011)
directors (in case of appointment of a is not related to any of the existing directors of
director) the Company.
5 Information as required under Circular Mr. Ashish Narayan Sakalkar is not debarred
No. LIST/COMP/14/2018-19 and from holding the office of a director by virtue
NSE/CML/ 2018/02 dated June 20, of any order by SEBI or any other authority
2018 issued by the BSE and NSE,
respectively
CIN: U24304MH2019PLC324187
Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi
Mumbai, Thane, Maharashtra, 400614, India
Phone No.: 022-49731419 / 49731411, Email id:
aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com
Web: www.asstonpharmaceuticals.com
ASSTON PHARMACEUTICALS LIMITED
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)
Annexure-B
SR.NO. PARTICULARS DETAILS
1 Name of the Internal auditor M/s Panchal S K & Associates.
2 Reason for Change Appointment
3 Date of appointment and terms of 04th September, 2026, by passing a
appointment resolution in the meeting of the Board of
Directors of the Company and approved by
the Members of the Company in 7th Annual
General Meeting held on 29th September,
2026.
4 Brief profile M/s. Panchal S K & Associates (est. 2017,
ICAI Reg. No. 145989W) is led by founder
partner Swati Panchal, a member of ICAI
since 2012. The firm comprises professionals
focused on adding value to clients’
businesses through technology-driven
practices and insights. Its experience spans
SMEs and larger corporates across various
industries.
5 Disclosure of relationship with directors Not related
CIN: U24304MH2019PLC324187
Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi
Mumbai, Thane, Maharashtra, 400614, India
Phone No.: 022-49731419 / 49731411, Email id:
aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com
Web: www.asstonpharmaceuticals.com